Wright State Physicians
Fairborn, Ohio, 45324, United States
Location status: Recruiting
NCT Number: NCT04036188
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Early Phase 1
Fairborn, Ohio, 45324, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Triamcinolone 0.1% daily
40,000 IU Vitamin D3 daily
Placebo daily
Time frame: Week 28
Subjects achieving a 50% improvement from baseline (PASI 50)
Time frame: Week 28
Subjects achieving a 1 point reduction from baseline
Time frame: Week 28
Subjects achieving a 50% reduction from baseline
Time frame: Week 28
Assess change through complete metabolic profile laboratory values
Time frame: Week 28
Assess change through parathyroid hormone level laboratory values
Time frame: Week 28
Assess change through 25-Hydroxyvitamin D laboratory values
Contact information is provided by the study sponsor or research team.
Manager, Clinical Research Operations
CONTACT
Regulatory Specialist
CONTACT
Wright State University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07116967
Plaque Psoriasis
Birmingham, Alabama, United States
View Trial DetailsNCT07683065
Metabolic Dysfunction-Associated Steatotic Liver Disease, Plaque Psoriasis
Badalona, Barcelona, Spain
View Trial DetailsNCT07250802
Plaque Psoriasis
Chula Vista, California, United States
View Trial DetailsNCT06382051
Arthritis, Arthritis, Psoriatic
Calgary, Alberta, Canada
View Trial Details